Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

EMD-1214063 displays potent and selective c-Met inhibition

April 27, 2010

Pfizer halts phase III trial of Sutent in liver cancer

April 26, 2010

Aragon secures financing to advance ARN-509

April 26, 2010

Genentech submits supplemental BLA to FDA for Herceptin in stomach cancer

April 26, 2010

Celtic Pharma evaluates Xerecept in pediatric patients with metastatic brain tumors

April 26, 2010

XL-647/sorafenib combination shows promise in preclinical models of HCC

April 26, 2010

Boehringer Ingelheim identifies new B-raf inhibitors

April 26, 2010

Delcath reports phase III data on Delcath PHP System-delivered melphalan

April 23, 2010

Genmab begins new next-generation antibody program HuMax-cMet

April 23, 2010

Nerviano Medical Sciences discovers new B-raf inhibitors for cancer therapy

April 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...